VCM
CGON icon

Versant Capital Management’s CG Oncology CGON Stock Holding History

Versant Capital Management’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.77K Hold
39
– – ﹤0.01% 2521
2026
Q1 		$2.64K Hold
39
– – ﹤0.01% 2518
2025
Q4 		$1.62K Hold
39
– – ﹤0.01% 2469
2025
Q3 		$1.57K Hold
39
– – ﹤0.01% 2447
2025
Q2 		$1.01K Buy
39
+26
+200% +$627 ﹤0.01% 2485
2025
Q1 		$318 Sell
13
-400
-97% -$11.3K ﹤0.01% 2441
2024
Q4 		$11.8K Buy
+413
New +$14.1K ﹤0.01% 1313

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Versant Capital Management's CGON Position: Q2 2026 in Review

Versant Capital Management held its CG Oncology (CGON) position steady in Q2 2026 at 39 shares worth $2.77K. The position accounts for ﹤0.01% of the portfolio, ranked #2521.

Versant Capital Management first reported a position in CGON in Q4 2024 and has held it in 7 quarters since. The position peaked at $11.8K in Q4 2024. 227 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

  • Versant Capital Management held 39 shares of CG Oncology worth $2.77K as of Q2 2026.
  • Versant Capital Management left its CG Oncology share count unchanged in Q2 2026.
  • CG Oncology made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #2521 holding.
  • Versant Capital Management first reported a position in CG Oncology in Q4 2024 and has held it in 7 quarters since.
  • Versant Capital Management's CG Oncology position peaked at $11.8K in Q4 2024.
  • 227 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.